3'-O-Methyl-evomonoside | 466-07-9

• 物质功能分类: 生物化工 - 中草药成分
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3'-O-Methyl-evomonoside
• 英文别名: 3-[(3S,5R,8R,9S,10S,13R,14S,17R)-3-(3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl)oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
• CAS: 466-07-9
• 化学式: C₃₀H₄₆O₈
• 分子量: 534.69
• InChiKey: VPUNMTHWNSJUOG-VZCPFXLZSA-N

物化性质

• 熔点：
  218-225°C
• 比旋光度：
  D23 -50.2° (CH3OH)
• 溶解度：
  可溶于氯仿（少许）、DMSO（少许）、甲醇（少许）、水（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  38
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  115
• 氢给体数：
  3
• 氢受体数：
  8

安全信息

• 危险品标志：
  T+
• 安全说明：
  S22,S36/37/39,S45
• 危险类别码：
  R26/27/28
• WGK Germany：
  3
• 危险品运输编号：
  UN 2811 6.1/PG 1
• RTECS号：
  FH4906100

制备方法与用途

生物活性

Neriifolin 是一种穿透中枢神经系统的强心苷，是一种 Na+, K+-ATPase 的抑制剂。它可靶向 beclin 1，抑制 LC3 相关吞噬体的形成，并改善实验性自身免疫性脑脊髓炎 (EAE) 的发展。此外，Neriifolin 还能诱导人肝癌 HepG2 细胞周期阻滞和凋亡。

体外研究

Neriifolin 在浓度为 0.1 μg/mL 的条件下（持续 48 小时），可诱导 HepG2 细胞凋亡。在 0-8 μg/mL 浓度范围内（持续 72 小时），Neriifolin 可降低 HepG2 细胞的存活率。同时，它还能引起 HepG2 细胞周期 S 和 G2/M 期阻滞，并刺激 HepG2 细胞凋亡。通过刺激 HepG2 细胞，Neriifolin 激活了 caspase-3、caspase-8 和 caspase-9 的活性，并上调 Fas 和 FasL 蛋白的表达水平。

文献信息

• Crystal characteristics, preparation processes and anticancer applications of 17beta-neriifolin crystal forms
  申请人：EnKang Pharmaceuticals (Guangzhou), Ltd.

  公开号：US11091510B2

  公开（公告）日：2021-08-17

  The present invention provides the preparation processes for several crystal forms of the compound 17beta-Neriifolin (17bNF) and use thereof in anti-tumor applications. The present invention provides preparation processes for four kinds of non-solvated crystal forms, amorphous powders and eleven kinds of solvated crystalline solids, including ethanol-solvated ones, of 17bNF that are not present in nature, and the identification and characterization of these crystal forms by crystallographic research methods such as X-ray powder diffraction. In addition, through vivo anti-tumor experiments with five of the crystal forms in nude mice, we provide anti-tumor and anti-cancer applications of the crystal forms of 17bNF.

  本发明提供了化合物 17beta-Neriifolin（17bNF）的几种晶型的制备工艺及其在抗肿瘤中的应用。本发明提供了自然界中不存在的 17bNF 的四种非溶解晶型、无定形粉末和十一种溶解晶型固体（包括乙醇溶解型）的制备工艺，并通过 X 射线粉末衍射等晶体学研究方法对这些晶型进行了鉴定和表征。此外，通过对其中五种晶体形态进行裸鼠体内抗肿瘤实验，我们提供了 17bNF 晶体形态的抗肿瘤和抗癌应用。
• CRYSTAL CHARACTERISTICS, PREPARATION PROCESSES AND ANTICANCER APPLICATIONS OF 17BETA-NERIIFOLIN CRYSTAL FORMS
  申请人：ENZHI (GUANGZHOU) PHARMACEUTICALS LIMITED

  公开号：US20200157139A1

  公开（公告）日：2020-05-21

  The present invention provides the preparation processes for several crystal forms of the compound 17beta-Neriifolin (17bNF) and use thereof in anti-tumor applications. The present invention provides preparation processes for four kinds of non-solvated crystal forms, amorphous powders and eleven kinds of solvated crystalline solids, including ethanol-solvated ones, of 17bNF that are not present in nature, and the identification and characterization of these crystal forms by crystallographic research methods such as X-ray powder diffraction. In addition, through vivo anti-tumor experiments with five of the crystal forms in nude mice, we provide anti-tumor and anti-cancer applications of the crystal forms of 17bNF.